FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating...

R3 Vascular Appoints Josh Smale as its Vice President of Global Clinical and Scientific Affairs R3 Vascular Inc. is pleased to announce the appointment of Josh Smale as its Vice President of Global Clinical and Scientific Affairs.

R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new President and CEO R3 Vascular, Inc. announced the closing of its $87 million Series B financing round and the appointment of a new President and Chief Executive Officer

Amaranth Presented MAGNITUDE (98 micron) Nine-Month Follow-up Clinical Results and Introduced DEFIANCE (85 micron) BRS Development Plan at TCT MOUNTAIN VIEW, CA , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Amaranth Medical, a medical device company developing next-generation bioresorbable scaffolds, provided an update on the company’s...